Oral Administration of 24,25(OH)2D3 Suppresses the Serum Parathyroid Hormone Levels of Dialysis Patients

Nephron ◽  
1991 ◽  
Vol 58 (3) ◽  
pp. 283-287 ◽  
Author(s):  
Dorit Ben-Ezer ◽  
Shraga Shany ◽  
Aviva Conforty ◽  
Jayson Rapoport ◽  
Samuel Edelstein ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Oral Administration ◽  
Dialysis Patients ◽  
Serum Parathyroid Hormone ◽  
Hormone Levels

scholarly journals Famotidine Reduces Serum Parathyroid Hormone Levels in Uremic Patients

Nephron ◽  
1991 ◽  
Vol 59 (2) ◽  
pp. 333-333
Author(s):  
Nurol Arik ◽  
Turgay Arinsoy ◽  
Murat Sayin ◽  
Ilgar Taşdemir ◽  
Ünal Yasavul ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Serum Parathyroid Hormone ◽  
Hormone Levels ◽  
Uremic Patients

scholarly journals Serum Parathyroid Hormone Levels and Renal Handling of Phosphorus in Patients with Chronic Renal Disease

1972 ◽  
Vol 35 (2) ◽  
pp. 213-218 ◽  
Author(s):  
MORDECAI M. POPOVTZER ◽  
WULF F. PINGGERA ◽  
MARTIN P. HUTT ◽  
JOHN ROBINETTE ◽  
CHARLES G. HALGRIMSON ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Renal Disease ◽  
Chronic Renal Disease ◽  
Serum Parathyroid Hormone ◽  
Renal Handling ◽  
Hormone Levels

Significant developmental elevation in serum parathyroid hormone levels in a large kindred with familial benign (hypocalciuric) hypercalcemia

1993 ◽  
Vol 7 (4) ◽  
pp. 378-378 ◽  
Author(s):  
Cynthia T. McMurtry ◽  
Francine W. Schranck ◽  
Denise A. Walkenhorst ◽  
William A. Murphy ◽  
David B. Kocher ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Serum Parathyroid Hormone ◽  
Hormone Levels

Falsely Elevated Serum Parathyroid Hormone Levels due to Immunoglobulin G in a Patient with Idiopathic Hypoparathyroidism*

1991 ◽  
Vol 72 (1) ◽  
pp. 217-222 ◽  
Author(s):  
KEIZO KASONO ◽  
KANJI SATO ◽  
TOMOHARU SUZUKI ◽  
EIJI OHMURA ◽  
REIKO DEMURA ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Immunoglobulin G ◽  
Elevated Serum ◽  
Serum Parathyroid Hormone ◽  
Hormone Levels

scholarly journals Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics

2020 ◽  
Author(s):  
Maria Dolores Arenas ◽  
Cristian Rodelo-Haad ◽  
M Victoria Pendón-Ruiz de Mier ◽  
Mariano Rodriguez
Keyword(s):  
Parathyroid Hormone ◽  
Standard Deviation ◽  
Secondary Hyperparathyroidism ◽  
Serum Phosphate ◽  
Dialysis Patients ◽  
Serum Parathyroid Hormone ◽  
Apparent Lack ◽  
Serum Pth ◽  
And Control ◽  
Possible Cause

Abstract Background In dialysis patients, non-adherence to oral cinacalcet adds complexity to the control of secondary hyperparathyroidism. The present study aims to evaluate the use of intravenous calcimimetic, etelcalcetide, in the control of secondary hyperparathyroidism in patients adherent and non-adherent to oral calcimimetics. Method The Simplified Medication Adherence Questionnaire was used to identify non-adherence. Almost half of the patients were non-adherent to the treatment with cinacalcet. Twenty-five patients (15 non-adherent) were switched from cinacalcet to etelcalcetide and were followed-up monthly for 8 months. Results Cinacalcet was discontinued for 1 week before the initiation of etelcalcetide. After this period, the serum PTH levels increased by2-fold in adherent patients, whereas it did not change in non-adherent patients suggesting that they were not taking the medication. Etelcalcetide progressively reduced serum parathyroid hormone (PTH) (mean ± standard deviation) from 818 ± 395 to 367 ± 289 pg/mL (P < 0.001) in non-adherents, and from 496 ± 172 to 228 ± 111 pg/mL (P < 0.01) in adherent patients with a mean dose of 7.0 ± 2.3 and 5.1 ± 1.2 mg in non-adherent and in adherent patients, respectively. Etelcalcetide increased the percentage of patients with PTH on target from 28% to 58%. Patients with serum calcium <8.4 mg/dL increased from 8% to 40%, although they remained asymptomatic. The percent of patients with serum phosphate on target increased from 40% to 65%. Conclusion The lack of adherence to cinacalcet is a possible cause of the apparent lack of response to oral calcimimetic. The use of etelcalcetide ensures compliance and control of secondary hyperparathyroidism in both non-adherent and adherent patients.

Sign in / Sign up

Export Citation Format

Share Document